Record Q2 volume and revenue exceeded guidance, with profitability achieved ahead of schedule. Strong demand and expanded payer coverage, especially for genome testing, set the stage for sustained growth, with significant improvements in collection rates and cash flow expected in late 2026 and 2027.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.